Hypertension is the most frequent medical complication of pregnancy. Pre-eclampsia is one of the main causes of maternal and fetal morbidity and mortality. Hypertension is the most common first sign of preeclampsia. Pre-eclampsia is also associated with fetal growth restriction, low birth weight, preterm delivery, small for gestational age infants and respiratory distress syndrome.
INTRODUCTION
HYPERTENSION is the most frequent medical complication of pregnancy, occurring in up to 10% of pregnancies. PRE-ECLAMPSIA is one of the main causes of maternal and fetal morbidity and mortality. Hypertension is the most common first sign of pre-eclampsia. Pre-eclampsia is also associated with fetal growth restriction, low birth weight, preterm delivery, small for gestational age (SGA) infants and respiratory distress syndrome (1).
Table 1. Definitions

Hypertension
A diastolic blood pressure of 90 mmHg or more
New hypertension
Hypertension at or after 20 weeks gestation in a woman with a diastolic blood pressure of less than 90 mmHg before 20 weeks Pre-existing hypertension A diastolic blood pressure pre-pregnancy or at booking (before 20 weeks) of 90 mmHg or more
New proteinuria
The presence of proteinuria as shown by 1+ (0.3 g/l) or more on proteinuria dipstick testing, a protein / creatinine ratio of 30 mg/mmol or more on a random sample or a urine protein excretion of 300 mg or more per 24 hours Significant proteinuria Urine protein excretion ≥300 mg per 24 hr Pre-eclampsia New hypertension and significant proteinuria at or after 20 weeks of pregnancy, confirmed if it resolves after delivery Superimposed pre-eclampsia The development of features of pre-eclampsia in the context of pre-existing hypertension, pre-existing proteinuria or both Blood tests relating to pre-eclampsia • Blood tests relating to pre-eclampsia are platelet count, serum creatinine, transaminases (AST or ALT as per local availability).
• Laboratory test results should be available within no more than 24 hours of the woman attending and the same day where practically possible, with a mechanism to review the tests and talk to the woman concerned, also within 24 hours.
• Use pregnancy-specific ranges for platelets, serum urate, transaminases and creatinine and a gestational age specific range for serum urate, as shown in Table 3 .
Laboratory tests for proteinuria
• Test to exclude or confirm significant proteinuria in women with 1+ dipstick proteinuria. A laboratory urinary protein creatinine (PCR) ratio from a random sample of less than 30 mg/mmol excludes • Platelet count <150 × 10 9 /L.
• Creatinine ≥90 micromol/L. significant proteinuria (A PCR > 30 mg/mmol does not reliably confirm or quantify proteinuria). A 24 hour urine collection of ≥300 mg/24 hr both confirms and quantifies proteinuria.
• For women with new hypertension between 90-99 mmHg and 1+ proteinuria, the decision to admit can be deferred until the results of the PCR are known. This is appropriate only when there are no maternal symptoms or clinical suspicion of fetal compromise. Arrange an umbilical artery Doppler and blood tests while waiting for the result of the PCR.
Umbilical artery Doppler
• Umbilical artery Doppler is the best test for predicting an at-risk fetus in women with preeclampsia. Abnormal umbilical artery Doppler thresholds include:
• Umbilical artery PI > 2SD;
• Absent or reverse end diastolic flow.
Antenatal inpatient management
The rationale for admitting women with a diagnosis of pre-eclampsia is the increased risks of placental abruption and eclampsia. These are likely to be managed more expeditiously if the woman is an inpatient.
A TPR chart of blood pressure (at least twice a day), urinalysis (daily) should be kept.
Any symptom relating or possibly relating to pre-eclampsia (headache, abdominal pain, breathlessness) should prompt a full set of observations (temperature, pulse, respiratory rate, blood pressure, oxygen saturations if breathless) and medical review.
Blood tests relating to pre-eclampsia should be performed at least twice weekly and recorded on the flow chart in the woman's handheld notes.
There is no need to repeat quantification of proteinuria in proven pre-eclampsia. If BP ≥140/90 mmHg, check every four hours with a manual sphygmomanometer.
Initial investigations
• Urinary protein (Dipstix, start 24 hr collection), protein / reatinine ratio.
• Midstream specimen of urine (MSU) to exclude infection (if leucocytes and / or nitrite+).
• Urine output must be accurately monitored and recorded.
• Full blood count (FBC) and platelets.
• Clotting screen is only required if platelets <100 × 10 9 /l or liver function test (LFT) is abnormal.
• Urea and electrolytes (U & Es) (creatinine should be <90 µmol/l).
• LFTs (serum aspartate amino transferase (AST) and alanine amino transferase (ALT) should be <30 iu/l).
• Glucose if ALT >150, acute fatty liver of pregnancy (AFLP) or diabetic.
• Blood film if HELLP suspected (haemolysis, elevated liver enzymes and low platelets -associated with higher maternal mortality).
• Group and save (G & S) and antibody screen.
Fetus
Clinical
• Assessment of gestation.
• Fundal height, presentation and estimated fetal weight (EFW).
• Fetal movements. Investigations • Cardiotocograph (CTG).
• Ultrasound scan for presentation, EFW and liquor volume.
• Umbilical artery Doppler studies (and uterine).
• Uterine Doppler studies (outcome worse if high respiratory infection / notches).
If BP is controlled and proteinuria is 0.3-0.5 g, the woman may be allowed home. However, she will need to be reviewed three times per week with weekly 24-hour urine collection. She should be admitted if the BP becomes out of control or proteinuria is >0.5 g/24 hr. The rationale for this strategy is the low incidence of complications if proteinuria is <0.5 g/24 hr.
Managing women with isolated new-onset proteinuria in pregnancy
Women with new-onset isolated proteinuria in pregnancy are usually regarded as falling somewhere within the pre-eclampsia spectrum. They may be regarded as a group that could go on to develop full-blown pre-eclampsia and kept under surveillance in the same way as women who have isolated pregnancy-induced hypertension. In the BEST study 10% of women with isolated proteinuria went on to eclampsia within one week. The comparable figure for women with isolated hypertension was 22% (3).
Management
These women should have the following monitoring:
• Day assessment unit twice per week for BP check, review of symptoms and PET bloods. Admission if BP ≥140/90 mmHg, symptoms or abnormal PET bloods.
• Repeat 24-hour protein collection every week. Admit if protein rises to ≥3 g/24 hours.
• Fetal growth scan every 4 weeks.
• Consider renal investigations.
• MSU on the first referral and review within 48 hours by an obstetric registrar.
Follow-up
It is extremely important that these women continue to have a regular review by their obstetrician.
MANAGEMENT OF HYPERTENSION
Pre-existing hypertension β-blockers and diuretics should be discontinued once pregnancy is confirmed. If treatment is required to keep the blood pressure <150/100 mmHg (allowing for the physiological fall in blood pres-sure in the first trimester), then treatment with methyl dopa should be commenced. If the blood pressure is satisfactory without treatment (which is often the case in women with well-controlled hypertension on monotherapy pre-pregnancy), the woman should be counselled that antihypertensive medication may be required at 26-30 weeks gestation. A plan should be made for monitoring of the blood pressure at least 3-4 weekly throughout pregnancy.
Women receiving calcium antagonists (nifedipine or amlodipine) or labetalol may continue these drugs in pregnancy.
Women receiving ACE inhibitors and angiotensin receptor blockers should ideally discontinue these drugs prior to pregnancy.
Pregnancy induced hypertension (PIH)
Management aims to control the blood pressure and undertake surveillance.
The aim of treatment of hypertension is to avoid severe hypertension (SBP >160 mmHg) and prolong gestation. Women without pre-eclampsia treatment of hypertension also avoid admission to hospital.
The antihypertensive agents used are the same regardless of the underlying cause of hypertension.
Pre-eclampsia
Methyldopa is the first-line treatment. Nifedipine is the second-line drug. Labetolol is a useful secondor third-line drug where there are no contra-indications to beta blockade. Labetalol or hydralazine are used for severe hypertension once the decision has been taken to deliver. Labetalol should be avoided in women with asthma.
Oral antihypertensive therapy
Drugs for the treatment of hypertension in pregnancy are given in Table 4 .
INTRAPARTUM MANAGEMENT
The decision to deliver should be made by the consultant obstetrician. Remember that initial stabilisation of the maternal condition leads to a safer delivery by whatever route.
DO NOT RUSH into delivery. If <34 weeks, try to stabilise and gain time for betamethasone to act. If >34 weeks, usually labour will be induced. Assess the state of the cervix, maternal condition and fetal wellbeing. Indications for operative vaginal delivery are not altered by hypertension. Inform neonatologists at an early stage.
Pre-eclampsia may progress intrapartum and a close watch should be kept on the blood pressure and symptoms remembering that PET is a multisystem disease, where end-organs (e. g. cardio-vascular, renal, central nervous, hepatic, coagulation and placenta) may be affected to a greater or lesser extent.
Intravenous access is required for all women with pre-eclampsia during labour and delivery. Oral antihypertensive treatment should continue through labour. Stabilisation of BP with oral treatment before induction or caesearan section (CS) makes hypertension in labour, delivery and the postpartum period easier to manage, and may avoid the need for parenteral therapy.
Analgesia during labour
Severe PET is not a contra-indication to epidural analgesia providing clotting is normal and platelets >75 × 10 9 /l. All women with proteinuric hypertension should have platelets and clotting checked on admission, otherwise delay in implementing epidural analgesia may occur. The anaesthetist need not wait for the results of a clotting screen unless the platelet count is <100 × 10 9 /l. If the platelet count is between 75-100, the epidural should only be sited if the clotting screen is normal.
Remember that vasoconstriction is a part of the pathophysiology of PET, and a very careful attention to fluid balance is mandatory.
Third stage:
Oxytocin 5IU should be given intramuscularly. NO syntometrine or ergometrine.
Anticonvulsant therapy in eclampsia
The risk of eclampsia in women with severe PET is reduced by more than 50% with the use of prophylactic MgSO 4 . Magnesium sulphate is the drug of choice for both prevention and treatment of eclampsia. Eclampsia should be treated with IV magnesium sulphate IV. Thereafter women receive a magnesium sulphate infusion to prevent further seizures. Consider anticonvulsant prophylaxis if the woman is symptomatic or has abnormal LFTs.
If seizure:
Recovery position & administer oxygen. Ensure adequate IV access.
Initial treatment (loading dose) (prophylaxis or treatment)
4 g (diluted to 20 ml in 5% dextrose or 0.9% sodium chloride) 10% MgSO 4 infused IV over 5-10 min.
Maintenance dose 5 g MgSO 4 in 50 ml running at 10 ml per hour (1 g/hr). This volume needs to be deducted from hourly maintenance fluid.
Contraindications
Cardiac disease, acute renal failure (must be discussed with senior obstetrician, usually same loading dose plus reduced maintenance dose). Myaesthenia gravis Use diazemuls, 10 mg, then 2.5 mg/hr OR rectal diazepam 10 mg/2.5 ml. Presence of patellar reflex, oxygen saturation and Mg levels MUST be recorded on the PET chart.
Duration of infusion
Dose alterations
Oliguria (≤80 ml over 4 hr) OR urea >10 mmol/l, cr Measure Mg levels 6 hourly >150 mmol/l ALT > 250 IV/l Measure Mg levels 6 hourly Mg level > 4 mmol/l Decrease maintenance dose to 0.5 g/hr Leads to fetal loss in animals; human first trimester use associated with fetal abnormalities; use in the second and third trimester associated with fetopathy, oligohydramnios, growth restriction, and neonatal anuric renal failure, which may be fatal. Eclampsia does not usually occur without premonitory symptoms (e. g. severe headache, visual disturbance, and epigastric pain). Symptoms should always be taken seriously. 44% of eclamptic fits occur after delivery (3). Thus, post-natal vigilance is essential, although the disease will resolve spontaneously in all but a few cases.
Recurrent seizures after starting Mg
Blood Pressure
• A BP of greater than 160/110 requires treatment (see below).
Do not forget that acute reduction in BP to </90 may precipitate fetal distress and therefore continuous CTG is necessary in the acute situation when fast acting drugs are used. It is important that BP is not allowed to fall precipitately (below 140/90) to avoid the risk of underperfusion of the patient's vital organs, i. e. brain, kidneys and placenta.
Oliguria is common, especially post delivery and especially in the context of prolonged oxytocin use. Urine output may incorrectly appear to be reduced if the fetal head is well down in the pelvis, so use a large-bore urinary catheter. As long as urine output >20 ml/hr, await resolution of PET. In case of prolonged oliguria (<80 ml/4 hr), check serum cre-atinine. Remember the risk of pulmonary oedema and avoid the temptation to give intravenous fluids to treat oliguria unless there is evidence of blood loss or hypovolaemia.
Until a diuresis occurs, blood should be taken regularly (initially 4-6 hourly) to monitor electrolytes, creatinine, FBC, clotting and LFTs. Diuresis usually signals resolution unless there is underlying disease, and gradual reduction in antihypertensives and anticonvulsants can begin.
ANAESTHETIC PROTOCOL FOR PET
Labour
Epidural analgesia is the preferred method of analgesia.
Contraindications: Platelet count <75 × 10 9 /l (beware of a rapidly falling platelet count).
Elevated activated partial thrombin time (APTT) or thrombin time (TT). Symptoms or signs of abnormal bleeding or clotting.
Maternal refusal. FLUID PRE-LOAD: Hartmann's solution (250-500 over one hour).
Then continue with Hartmann's solution at 85 ml/hr.
Caesarean section
If ranitidine has not been given within the last 12 hr, give 50 mg IV.
Both epidural and spinal anaesthesia are suitable for CS.
Epidural anaesthesia usually provides very stable cardiovascular parameters.
Spinal anaesthesia can be employed as a part of a combined spinal epidural technique (CSE), the intrathecal dose of heavy bupivacaine 0.5% can be reduced (1.7-2.0 ml). Intrathecal diamorphine 250-300 µg or fentanyl 15-25 µg should be given with bupivacaine. In greater than 90% of mothers this solution will provide adequate anaesthesia for CS. In rare cases when it does not, small increments (3 ml of ropivacaine 0.75%) can be given through the epidural catheter.
However, if the platelets are falling, a single shot spinal anaesthesia may be more appropriate. A 25-27 g spinal needle will cause less trauma than the larger epidural needle. 2-2.2 ml of heavy bupivacaine with fentanyl or diamorphine should be used. Spinal anaesthesia is not associated with a catastrophic fall in blood pressure. Vasopressors should be used as required.
FLUID PRE-LOAD: Elective CS If no CVP, preload = 500 ml Hartmann's solution.
CVP ≥ 2 mmHg -500 ml Colloid. CVP > 2 mmHg -500 ml Hartmann's (over 15 min) prior to block.
Maintain 85 ml/hr and replace blood loss. Phenylephrine / ephedrine as required to maintain pressure.
Emergency LSCS If no CVP, extend epidural block without additional fluid.
No functioning block: As above. Functioning block: CVP ≤ 2 mmHg -500ml Hartmann's. CVP > 2 mmHg -Extend block without additional fluid.
General anaesthesia
In addition to the rapid sequence induction, alfentanil 1-2 mg should be given prior to intubation to obtund the hypertensive response. The induction dose of thiopentone should be 5-6 mg/kg. Consider using intra-arterial pressure monitoring. Mg-SO 4 (2 g) may be necessary prior to surgery. If the mother has received MgSO 4 , the degree of muscle relaxation must be carefully monitored. Labetolol may still be required at intubation and extubation.
No non-steroidal anti-inflammatory drugs (NSAIDS) (e. g. diclofenac) for at least 48 hr postpartum due to potential adverse effects on the renal and platelet function.
